Holen Sie sich die Stockscreener-App
1.94
8.99%
0.16
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
Price to book forward of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Enterprise value of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Total revenue of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
RTW Investments, LP Expands Tenax Therapeutics (TENX) Stake Desp - GuruFocus
Tenax Therapeutics (TENX) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Israel Englander funds hold over 5% of Tenax Therapeutics (TENX) - Stock Titan
TENX Q2 2026 Earnings: Narrower Loss Per Share Fails to Offset Stock DeclineEPS Revision Trend - vinanet.vn
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX) - GlobeNewswire
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
Price-Driven Insight from (TENX) for Rule-Based Strategy - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock - Stock Titan
Venrock group (TENX) discloses 1.57M-share warrant-based stake in Tenax - Stock Titan
Perceptive Advisors (TENX) reports beneficial ownership of 1.7M Tenax Therapeutics shares - Stock Titan
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - Kalkine
Tenax Therapeutics (TENX) holder BVF reports 3.11M shares, big warrant overhang - Stock Titan
Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants - Stock Titan
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) - Business Wire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares - Stock Titan
Tenax Therapeutics (TENX) Rallies 6.4% to $1.83, Approaching Key ResistanceNarrow Range Breakout - Vinanet
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics - Morningstar
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) - Morningstar
Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants - Stock Titan
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tenax Therapeutics downgraded to Neutral after ... - Pluang
Tenax Stock Plunges 89% After PH-HFpEF Trial Misses Main Goal, But Subgroup Data Offers Hope - finance.biggo.com
TENX Downgraded by Chardan Capital -- Price Target Lowered to $5 - GuruFocus
CCORF Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Neutral at Chardan Capital - MarketBeat
TENX Maintained by Guggenheim -- Price Target Lowered to $4.00 - GuruFocus
TENX Downgraded by Evercore ISI Group -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Downgraded by Evercore to "In-Line" - MarketBeat
A Quick Look at Today's Ratings for Tenax Therapeutics(TENX.US), With a Forecast Between $4 to $4 - Moomoo
Leerink Partners Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss - Investing.com South Africa
TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - Bitget
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 - marketscreener.com
Tenax Therapeutics’ stock crashes on Phase III trial failure - Yahoo Finance
We're Not Very Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Rate - simplywall.st
TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26 - Bitget
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF PatientsSlideshow (NASDAQ:TENX) 2026-08-11 - Seeking Alpha
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case - MarketBeat
Tenax Therapeutics (TENX) Stock Crashed: Here Is Why - top1markets.com
TENAX THERAPEUTICS INC : CANACCORD GENUITY CUTS TARGET PRICE TO $4 FROM $35 - Bitget
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90% - lincolnjournal.com
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson - GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week LowHere's Why - MarketBeat
William Blair downgrades Tenax Therapeutics stock rating on trial results By Investing.com - Investing.com UK
TENX Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Chapel Hill drug developer's stock plunges 90% after trial setback - The Business Journals
William Blair Downgrades Tenax Therapeutics(TENX.US) to Hold Rating - Moomoo
William Blair downgrades Tenax Therapeutics stock rating on trial results - Investing.com Nigeria
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback - Benzinga
Tenax drug trial misses mark, shares plunge 90% - Business North Carolina
Tenax, Sionna Shares Sink After Trial Failures -- WSJ - Bitget
Tenax Therapeutics shares plunged 87.2% after the company's heart drug failed to meet the primary endpoint in a late-stage study. - Bitget
Tenax Therapeutics (TENX) Shares Collapse 89% After Phase 3 Tria - GuruFocus
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):